MedPageToday
MedPage Today) — Patients with advanced non-progressing gastrointestinal stromal tumors (GIST) who discontinued imatinib had more rapid progression, faster development of resistance, and worse overall survival (OS), a small randomized trial showed…
Read More
Strong Support for Not Interrupting Imatinib Treatment in Advanced GIST
MedPage Today) — Patients with advanced non-progressing gastrointestinal stromal tumors (GIST) who discontinued imatinib had more rapid progression, faster development of resistance, and worse overall survival (OS), a small randomized trial showed…